Sugi Predict

Sugi Predict / Compounds / SCHEMBL23628951

SCHEMBL23628951

SCHEMBL23628951

COC(=O)c1ccc(N)c(OCc2ccsc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX1 Q96LB2 1/20 0.46
▸ MAPT P10636 4/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ LMNA P02545 3/20 0.43
▸ LNPEP Q9UIQ6 6/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5805287 0.82 HPGD (0.58) MAPTCYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL23629000 0.81 AR (0.52) MRGPRX1MAPTCYP3A4CYP1A2CYP2C9
SCHEMBL23628945 0.81 LOXL2 (0.58) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL23628989 0.78 CYP3A4 (0.51) MRGPRX1MAPTCYP3A4CYP1A2CYP2C9
SCHEMBL31451783 0.78 KDM4E (0.51) MAPTCYP3A4KDM4EALDH1A1HPGD
SCHEMBL23629017 0.78 DNMT1 (0.50) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL223446 0.77 HSD17B10 (0.55) MAPTCYP1A2SMN1; SMN2KDM4EALDH1A1
SCHEMBL2034752 0.76 BRD4 (0.51) MRGPRX1MAPTCYP3A4CYP1A2ALDH1A1
SCHEMBL20602048 0.76 MAPT (0.53) MAPTCYP1A2SMN1; SMN2KDM4EALDH1A1
SCHEMBL7345433 0.75 MAPT (0.56) MAPTCYP3A4CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria UNIVERZA V LJUBLJANI (SI) 2025-03-25 — — US disclosed
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA UNIVERZA V LJUBLJANI (SI) 2021-10-21 — — US disclosed
EP-3847172-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA Univerza v Ljubljani (SI) 2021-07-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323957-A1 NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA TOP1, TOP2A, TOP2B MRGPRX1 3097/4885MAPT 2932/4885CYP3A4 643/4885
US-12258342-B2 Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria TOP1, TOP2A, TOP2B MRGPRX1 3474/4885MAPT 2543/4885CYP3A4 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.